PT-141 is a melanocortin receptor agonist with a development status of "fda-approved (branded form)". The Institute rates the strength of its published evidence as strong. A melanocortin agonist approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
The distinction that matters most when reading about PT-141 is between what has been demonstrated and what has been proposed. Mechanistic plausibility is not evidence of effect, and a compound can have a well-characterised receptor interaction while producing no measurable clinical benefit. That gap is where most of the confusion in this space lives.
Sample sizes in the PT-141 literature are small enough that individual studies should be read as hypothesis-generating rather than conclusive. Effect sizes reported in small trials are systematically inflated, and the pattern is well documented across pharmacology generally.
The Institute has independently tested 6 PT-141 samples from 5 companies. 83% met their label claims on purity and content. Measured purity ranged from 95.1% to 99.3%, averaging 97.7%. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
